AKRO
Akero Therapeutics Inc.
$54.20
-$0.06(-0.11%)
59
Overall
60
Value
75
Tech
42
Quality
Market Cap
$3.69B
Volume
1.14M
52W Range
$21.34 - $58.40
Target Price
$67.44
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $45.7M | $80.2M | $100.9M | $115.2M | $172.9M | $285.4M | ||
| Research & Development | $37.0M | $64.9M | $81.8M | $85.3M | $141.8M | $247.5M | ||
| Research Expense | $37.0M | $64.9M | $81.8M | $85.3M | $141.8M | $247.5M | ||
| Selling, General & Administrative | $8.6M | $15.2M | $19.1M | $29.9M | $31.1M | $37.9M | ||
| General & Administrative Expenses | $8.6M | $15.2M | $19.1M | $29.9M | $31.1M | $37.9M | ||
| Salaries & Wages | -- | -- | -- | -- | $21.5M | $29.7M | ||
| Amortization | -- | -- | -- | $204.0K | $448.0K | $607.0K | ||
| Other Operating Expenses | $-237.0K | $-407.0K | $-603.0K | $-746.0K | $-1.1M | $-2.5M | ||
| OPERATING INCOME | ||||||||
| Operating income | $-45.7M | $-80.2M | $-100.9M | $-115.2M | $-172.9M | $-285.4M | ||
| EBITDA | $-43.9M | $-80.1M | $-100.7M | $-111.3M | $-79.8M | $-182.1M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $739.0K | $3.1M | $4.7M | ||
| Intinc | -- | -- | -- | $3.9M | $24.2M | $38.0M | ||
| Net Non-Operating Interest Income/Expense | -- | -- | -- | $-3.1M | $21.1M | $33.4M | ||
| Other Income/Expense | $-1.9M | $-950.0K | $-85.0K | $3.9M | $-233.0K | $-678.0K | ||
| Other Special Charges | $1.9M | $947.0K | $109.0K | $-264.0K | $-79.0K | $-517.0K | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-43.8M | $-80.2M | $-100.8M | $-111.3M | $-80.3M | $-182.7M | ||
| Pre-Tax Income | $-43.8M | $-79.2M | $-100.8M | $-112.0M | $-151.5M | $-252.1M | ||
| INCOME TAX | ||||||||
| Tax Provision | $-9.4M | $-20.7M | $30.6M | $41.8M | $68.4M | $64.7M | ||
| NET INCOME | ||||||||
| Net Income | $-43.8M | $-79.2M | $-100.8M | $-112.0M | $-151.8M | $-252.1M | ||
| Net Income (Continuing Operations) | $-43.8M | $-79.2M | $-100.8M | $-112.0M | $-151.8M | $-252.1M | ||
| Net Income (Discontinued Operations) | $-43.8M | $-79.2M | $-100.8M | $-112.0M | $-151.8M | $-252.1M | ||
| Net Income (Common Stockholders) | $-43.8M | $-79.2M | $-100.8M | $-112.0M | $-151.8M | $-252.1M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-248.9M | ||
| TOTALS | ||||||||
| Total Expenses | $45.7M | $80.2M | $100.9M | $115.2M | $172.9M | $285.4M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $15.1M | $31.5M | $34.8M | $39.0M | $52.6M | $67.1M | ||
| Average Shares Outstanding (Diluted) | $15.1M | $31.5M | $34.8M | $39.0M | $52.6M | $67.1M | ||
| Shares Outstanding | $28.6M | $34.8M | $35.0M | $47.0M | $80.0M | $79.6M | ||
| Basic EPS | $-2.9 | $-2.52 | $-2.89 | $-2.87 | $-2.89 | $-3.75 | ||
| Basic EPS (Continuing Operations) | $-2.9 | $-2.52 | $-2.89 | $-2.87 | $-2.89 | $-3.75 | ||
| Diluted EPS | $-2.9 | $-2.52 | $-2.89 | $-2.87 | $-2.89 | $-3.75 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-2.89 | $-2.87 | $-2.89 | $-3.75 | ||
| OTHER METRICS | ||||||||
| Other Gand A | $8.6M | $15.2M | $19.1M | $29.9M | $31.1M | $37.9M | ||
| Rent And Landing Fees | $305.0K | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AKRO | $54.20 | -0.1% | 1.14M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |